Viewing stories tagged shareholder
19 February 2018
Shareholder Update February 2018
In this issue:
>> New sites open for the DEP® docetaxel phase 2 trial
>> DEP® cabazitaxel phase 1 / 2 trial commences
>> VivaGel® BV NDA submission lodged under Fast Track program
>> VivaGel® BV approved by TGA
>> DEP® irinotecan progressing towards the clinic
>> AstraZeneca-Starpharma collaboration
>> Extensive global licensing negotiations for VivaGel® BV
>> Positive market research findings for VivaGel® BV
>> Q2 Cashflow Report at 31 December 2017
>> OTCQX market recognition
>> Starpharma News & Events
>> Outlook
Download: Shareholder Update February 2018 (pdf file, 1.5mb)
|
18 October 2017
Shareholder Update October 2017
In this issue:
>> DEP® docetaxel achieves positive phase 1 results and commences phase 2
>> AZ presents first DEP® candidate AZD0466 – a Bcl2/xL inhibitor
>> Successful VivaGel® BV phase 3 results
>> Update on other internal DEP® candidates
>> Grant awarded to Starpharma-Monash
>> Starpharma and Peter Mac Cancer Centre awarded grant
>> FY17 Financial results; >$60M cash at 30 June
>> Annual Report and Annual General Meeting
>> Starpharma News & Events
Download: Shareholder Update October 2017 (pdf file, 1.3mb)
|
4 July 2017
Shareholder Update July 2017
In this issue:
>> Starpharma sells Agrochemicals business to Agrium for $35M cash
>> DEP® irinotecan outperforms irinotecan in multiple cancer models
>> DEP® docetaxel, DEP® cabazitaxel and scale-up facilities
>> AstraZeneca pays US$2M DEP® milestone to Starpharma
>> VivaGel® BV phase 3 results timing and commercialisation
>> VivaGel® condom launched in Canada
>> Sale of Ansell's Sexual Wellness division
>> Starpharma News & Events
Download: Shareholder Update July 2017 (pdf file, 710kb)
|
19 January 2017
Shareholder Update January 2017
In this issue:
›› Enrolment completed for phase 3 program: VivaGel® BV for prevention of recurrence
›› VivaGel® BV granted QIDP and Fast Track designation by US FDA
›› Favourable revision to FDA guidance for BV Treatment
›› VivaGel® condom approved in Canada; licensed in China and Iran
›› New DEP® partnered programs with AstraZeneca and world leading antibody-drug conjugate companies
›› DEP® docetaxel phase 1 program in final expansion phase; preparations underway for phase 2
›› DEP® cabazitaxel shows no neutropenia
›› DEP® irinotecan internal program shows superior performance
Download: Shareholder January 2017 (pdf file, 751kb)
|
13 April 2016
Shareholder Update April 2016
In this issue:
> Message from the CEO
> Adama licenses Priostar® for 2,4-D
> DEPTM cabazitaxel shows superior performance
> Starpharma's Targeted DEPTM conjugates - compelling results in an area of high interest
> AstraZeneca selects second DEPTM candidate
> Starpharma long standing collaborator ranked 4th in the world
> Starpharma signs licence with Aspen for commercialisation of VivaGel® BV in Australia and New Zealand
> MOU for VivaGel® condom in China
> Half-year financial results
> Bio-Europe® conference
Download: Shareholder Update April 2016 (pdf file, 1MB)
|
29 October 2015
Shareholder Update October 2015
In this Issue:
› EU marketing approval granted for VivaGel® BV
› Multi-product DEP® license with AstraZeneca
› VivaGel® BV: Symptomatic Relief and Treatment of BV/Prevention of recurrence
› VivaGel® condom
› Phase 1 DEP® docetaxel trial update
› Agrochemicals
› Starpharma in the News
› Starpharma full year financial results
› Presentations and conferences
Download: Shareholder Update October 2015 (pdf file, 994kb)
|
23 March 2015
Shareholder Update March 2015
In this Issue:
› Phase 1 DEP™ docetaxel clinical trial update
› DEP™ docetaxel in the news
› Partner news
› Starpharma targeting key growth areas in Oncology
› Bacterial vaginosis: Prevention of recurrence/Symptomatic relief
› VivaGel® condom
› Corporate news
› Starpharma half yearly financial results
Download: Shareholder Update March 2015 (pdf file, 1MB)
|
7 October 2014
Shareholder Update October 2014
In this Issue:
› Encouraging clinical data for DEP™ docetaxel
› VivaGel® condom approved for sale in Australia – Launch imminent
› VivaGel® for BV: SPA agreement for Phase 3 and commercialisation activities for Symptomatic Relief
› Starpharma completes $18M Placement; launches $5M SPP
› Dendrimer-enhanced agrochemicals
› Full Year 2014 annual financial results
Download: Shareholder Update October 2014 (pdf file, 1MB)
|
12 June 2014
Shareholder Update: June 2014
In this issue:
› VivaGel® BV prevention of recurrence: start of phase 3 trials close
› R&D tax incentive cash received
› DEP™ docetaxel trial progressing well
› VivaGel®-coated condom: preparing for launch
› VivaGel® BV symptomatic relief product: commercial and regulatory progress
› Strong results for dendrimer enhanced agrochemicals
Download: Shareholder Update: June 2014 ( pdf file, 2MB)
|
17 December 2013
Shareholder Update: December 2013
In this issue:
› Dendrimer-Docetaxel to enter human clinical trials
› VivaGel® Phase 3 trial for prevention of recurrent BV
› VivaGel®-coated condom: Consumer feedback
› Impressive results for Dendrimer-Enhanced Oxaliplatin
› Progress continues in agrochemical activities
› Appointment of Rob Thomas
› SPL TV – a new channel
Download: Shareholder Update: December 2013 ( pdf file, 1MB)
|
24 May 2013
Shareholder Update: May 2013
In this issue:
› VivaGel® update
› New agrochemical partnership
› SPL7013 shows therapeutic potential in viral conjunctivitis
› Positive dendrimer-doxorubicin results
› Key patents obtained
› R&D tax refund received
› Momentum builds in nanomedicine
› Substantial holders increase their stake
Download: Shareholder Update: May 2013 ( pdf file, 1MB)
|
19 December 2012
Shareholder Update: December 2012
In this issue:
› Phase 3 clinical trial results for treatment of bacterial vaginosis
› Rapid resolution of symptoms; strong patient acceptability for VivaGel®
› Taxotere’s anti-cancer effect boosted with Starpharma’s dendrimer technology
› Turning over a new leaf in the world of agrochemicals
› Starpharma wins Janssen Company of the Year Award
Download: Shareholder Update: December 2012 ( pdf file, 1MB)
|
